References
Gal P, Oles KS, Gilman JT, Weaver R (1988) Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. Neurology 38(3):467–471
Clancy RR (2006) Summary proceedings from the neurology group on neonatal seizures. Pediatrics 117(3 Pt 2):S23–S27. doi:10.1542/peds.2005-0620D
Alfonso I, Alvarez LA, Gilman J, Dunoyer C, Yelin K, Papazian O (2000) Intravenous valproate dosing in neonates. J Child Neurol 15(12):827–829
Uberall MA, Trollmann R, Wunsiedler U, Wenzel D (2000) Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology 54(11):2188–2189
Yu KT, Mills S, Thompson N, Cunanan C (2003) Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 44(5):724–726
Tulloch JK, Carr RR, Ensom MH (2012) A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures. J Pediatr Pharmacol Ther 17(1):31–44
Hermida J, Tutor JC (2005) A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients. J Pharmacol Sci 97(4):489–493
Lheureux PE, Penaloza A, Zahir S, Gris M (2005) Science review: carnitine in the treatment of valproic acid-induced toxicity—what is the evidence? Crit Care 9(5):431–440. doi:10.1186/cc3742
Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE (2013) Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 23(4):236–241. doi:10.1097/FPC.0b013e32835ea0b2
Price KE, Pearce RE, Garg UC, Heese BA, Smith LD, Sullivan JE, Kennedy MJ, Bale JF Jr, Ward RM, Chang TK, Abbott FS, Leeder JS (2011) Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. Clin Pharmacol Ther 89(6):867–874
Sztajnkrycer MD (2002) Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40(6):789–801
Silva MF, Aires CC, Luis PB, Ruiter JP, IJ L, Duran M, Wanders RJ, de Tavares AI (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31(2):205–216
Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC, Chang CC, Chang WN, Chuang YC (2014) Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine (Baltimore) 93(11):e66. doi:10.1097/MD.0000000000000066
Nagy A, Budi T, Temesvari M, Szever Z, Szabo PT, Monostory K (2015) Adverse events in a newborn on valproate therapy due to loss-of-function mutations in CYP2C9. Epilepsy & behavior case reports 4:86–87
Inoue K, Takahashi T, Yamamoto Y, Suzuki E, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K (2015) Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. Seizure 33:76–80
Acknowledgments
Pavla Pokorna is supported by the General University Hospital Project (MH CZ-DRO VFN 64165) (Ministry of Health, Czech Republic - Conceptual Development of Research Organization) (MH CZ–DRO, name of organization; VFN - General Faculty Hospital, name of institution), and an unrestricted research grant of the Intensive Care of the Erasmus MC-Sophia Childrens Hospital (name of institution).
Author information
Authors and Affiliations
Corresponding author
Additional information
Dick Tibboel is the lead author of this paper.
Rights and permissions
About this article
Cite this article
Pokorná, P., Hronová, K., Šíma, M. et al. Valproic acid—induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report. Eur J Clin Pharmacol 73, 647–649 (2017). https://doi.org/10.1007/s00228-017-2208-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-017-2208-4